Tina Wilson, MD
Infectious Disease · Jackson, TNNPI 1376579854
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 34.5% of the total. 2025 is the largest year on record at $849, 4.7 times the $179 reported in 2019.
Across 64 payments — averaging $24.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$532
- Merck$390
- Melinta Therapeutics, LLC$146
- Paratek Pharmaceuticals, Inc.$110
- Insmed, Inc.$93
- Shionogi Inc$71
- plus $199 from 6 others
What the payments were for
- Food & beverage$1,51598%
- Education$272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $532 |
| Merck | 19 | $390 |
| Melinta Therapeutics, LLC | 7 | $146 |
| Paratek Pharmaceuticals, Inc. | 5 | $110 |
| Insmed, Inc. | 5 | $93 |
| Shionogi Inc | 3 | $71 |
| Lundbeck LLC | 3 | $66 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $47 |
| Mayne Pharma Commercial LLC | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Nabriva Therapeutics, PLC | 1 | $22 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBLAVEO$125
How this compares
$1,542 in reported general payments places this provider in the 70th percentile of 156 infectious disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 29 | $19,633 |
| CeftriaxoneCeftriaxone Sodium | 38 | $14,454 |
| Nafcillin Sodium | 20 | $8,615 |
| Vancomycin Hcl | 41 | $6,334 |
| ErtapenemErtapenem Sodium | 15 | $4,516 |
| Ampicillin Sodium | 21 | $3,437 |
| Doxycycline Hyclate | 15 | $245 |
| Metronidazole | 11 | $129 |
| Levofloxacin | 12 | $82 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Jackson
- Barbara MenziesJackson$3K
- Julie AntiqueJackson$2K
- Alfred AiyanyorJackson$2K
- Michael GelfandMemphis$486K
- Kerry ClevelandMemphis$426K
- Mark PierceCookeville$246K
- Michael DeckerBaxter$108K
- James SizemoreChattanooga$101K
- John KoetheNashville$91K
- Elizabeth PhillipsNashville$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.